文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌减边IMRT/IGRT的随机II期试验:晚期盆腔毒性与生活质量

Image-guided intensity-modulated radiotherapy with reduced margins in patients with prostate cancer: Results of the RCMIGI randomized phase II trial.
PubMed 文献 · Radiother Oncol · 2025-12-07

这项随机II期试验(NCT03254420)纳入74例低至中危前列腺癌患者,按1:2随机接受标准边距或减边距IMRT/IGRT。减边距组联合CBCT与实时追踪(Calypso® 4D)并将前列腺边距设为3 mm。两组≥2级晚期盆腔毒性均低,减边距组2年泌尿症状评分显著更低(12.3 vs 21.2,p=0.028)。

要点

  • 减边距组前列腺边距3 mm,对照组1 cm(后方0.5 cm)。
  • 两组≥2级晚期盆腔毒性各5例,发生率均低。
  • 减边距组2年泌尿症状评分显著更低(12.3 vs 21.2,p=0.028)。

核心结论

  • 减边距IMRT/IGRT可行,可能改善部分剂量学结果和患者报告的泌尿症状。
  • 两组晚期盆腔毒性发生率均低,减边距可能改善患者报告的泌尿症状。

研究设计与样本

  • 随机II期试验(NCT03254420),2016年8月至2022年5月纳入74例低至中危前列腺癌患者。
  • 按1:2随机分为标准边距对照组(n=30)和减边距试验组(n=44)。
  • 对照组IGRT使用CBCT,试验组联合CBCT与实时追踪(Calypso® 4D)并采用更小边距。
  • 主要终点为≥2级晚期盆腔毒性(CTCAE v4.03)。

主要发现

  • 两组各5例发生≥2级晚期盆腔毒性。
  • 研究期间试验组88.6%(95%CI:75.4-96.2)和对照组80.8%(95%CI:60.6-93.4)的患者未发生≥2级晚期盆腔毒性。
  • 常规分割下试验组直肠(V70Gy、D50%)和膀胱(D50%、V70Gy、V76Gy)剂量显著更低(p<0.01)。
  • 常规分割下试验组直肠(D1%、V76Gy)和膀胱(V80Gy)剂量显著更高(p<0.01)。
  • 放疗后2年试验组泌尿症状评分显著更低(均值12.3 vs 21.2,p=0.028)。

关键数值与推荐

  • 试验组前列腺边距3 mm,对照组1 cm(后方0.5 cm)。
  • 主要终点为≥2级晚期盆腔毒性,按CTCAE v4.03评估。
  • 毒性由医生按CTCAE评分,同时采用患者报告的生活质量结局。

临床怎么用

  • 对低至中危前列腺癌,可考虑CBCT联合实时追踪实现减边距IMRT/IGRT以改善泌尿症状。
  • 减边距时需注意直肠D1%、V76Gy和膀胱V80Gy等高剂量区参数可能升高。
  • 应结合医生评分CTCAE和患者报告结局共同评估晚期毒性。

局限性

  • 样本量较小(共74例),为II期试验。
  • 原文未报告随访时长、统计效能及多中心/单中心设计等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Intensity-modulated (IMRT) and image-guided (IGRT) radiotherapies reduce radiation-induced toxicities in localized prostate cancer. This randomized phase II trial (NCT03254420) evaluated late pelvic toxicity (LPT) and quality of life after IMRT/IGRT with standard or reduced margins in patients with low- to intermediate-risk prostate cancer. MATERIALS AND METHODS: Between August 2016 and May 2022, 74 patients were randomized (1:2) to IMRT/IGRT with standard (Control, n = 30) or reduced (Experimental, n = 44) margins. Control IGRT used cone-beam computed tomography (CBCT), while experimental IGRT combined CBCT with real-time tracking (Calypso® 4D Localization System) and smaller margins. Prostate margins were 3 mm in the Experimental arm versus 1 cm (0.5 cm posteriorly) in the Control arm. The primary endpoint was grade ≥ 2 LPT (CTCAE v4.03). Toxicities were assessed by physician-scored CTCAE and patient-reported quality-of-life outcomes. RESULTS: Grade ≥ 2 LPT occurred in 5 patients in each arm. Over the study period, 88.6 % (95 % CI: 75.4-96.2) of patients in the Experimental arm and 80.8 % (95 % CI: 60.6-93.4) in the Control arm did not experience a grade ≥ 2 LPT. Under conventional fractionation, the Experimental arm had significantly lower rectal (V70Gy, D50%) and bladder (D50%, V70Gy, V76Gy) doses (p < 0.01), but higher rectal (D1%, V76Gy) and bladder (V80Gy) doses (p < 0.01). At two years post-radiotherapy, urinary symptom scores were significantly lower in the Experimental arm (mean 12.3 vs. 21.2, p = 0.028). CONCLUSION: IMRT/IGRT with reduced margins is feasible and may improve some dosimetric outcomes. Both arms had low LPT rates, but reduced margins may improve patient-reported urinary symptoms.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Riou O, Fenoglietto P, Jarlier M, et al. Image-guided intensity-modulated radiotherapy with reduced margins in patients with prostate cancer: Results of the RCMIGI randomized phase II trial. Radiother Oncol. 2025. PMID: 41365376. doi:10.1016/j.radonc.2025.111322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。